Association of Ultrasound Findings with Decision to Continue Down Syndrome PregnanciesPerry S. · Woodall A.L. · Pressman E.K.
Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Rochester, Rochester, N.Y., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Objective: To evaluate the association of ultrasound findings and other factors with the decision to terminate trisomy-21-affected pregnancies. Methods: We performed a retrospective analysis of trisomy-21-affected pregnancies diagnosed prior to 24 weeks’ gestation. Data were collected on maternal age, indications for prenatal diagnosis, gestational age at diagnosis, marital status, race, parity and ultrasound findings. Logistic regression, χ2, t test and Fishers exact test were used for statistical analysis. Results: Fifty-nine pregnancies were identified with a termination rate of 72.9%. Termination rates were significantly lower in patients with major (50%) or minor (64%) ultrasound abnormalities than in patients with normal ultrasound exams (92%), p = 0.026 and 0.022, respectively. Patients who chose terminations were older (36.1 vs. 32.3), but this did not reach statistical significance (p = 0.059). Conclusion: Patients with abnormal ultrasound results were more likely to continue a trisomy 21 pregnancy.
© 2007 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.